



Sinclair IS Pharma plc

Completion of Acquisition and admission of shares

LONDON - 15 December 2011 - Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair IS" or "the Company"), the international specialty pharmaceutical company, is pleased to announce that, further to the Company's announcement of 8 December 2011, the Acquisition of Advanced Bio-Technologies, Inc. is now complete and the Consideration Shares have today been admitted to trading on AIM.

Following the issue of the Consideration Shares, which rank pari passu with the Company's existing ordinary shares, the Company will have 400,802,790 ordinary 1p shares in issue, each share carrying the right to one vote. The Company does not hold any ordinary shares in Treasury.

The above figure of 400,802,790 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Services Authority's Disclosure and Transparency Rules.

Ends

Sinclair IS Pharma plc
Chris Spooner
Alan Olby

Tel: +44 (0) 20 7467 6920

Jefferies International Limited (NOMAD and Broker)
Julian Smith
Thomas Rider

Tel: +44 (0) 20 7029 8000

FTI Consulting
Ben Atwell
Stephanie Cuthbert

Tel: +44 (0) 20 7831 3113

Notes to Editors:

About Sinclair IS Pharma plc – www.sinclairispharma.com

Sinclair IS Pharma is an international specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through advanced surface technology and innovative delivery systems. The Company has a growing sales and marketing operation with a direct sales presence in the top five European markets and an extensive marketing partner network across selected developed and emerging markets.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.